Manufacturers running legacy PROMIS or first-gen MES can apply 25% of current maintenance spend toward a modern Eyelit MOM/MES subscription. Legacy PROMIS and first-generation MES platforms now ...
Zacks Investment Research on MSN
All you need to know about Promis Neurosciences (PMN) rating upgrade to buy
Promis Neurosciences (PMN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...
Zacks Investment Research on MSN
Wall Street analysts see a 230.23% upside in Promis Neurosciences (PMN): Can the stock really move this high?
Shares of Promis Neurosciences (PMN) have gained 3.3% over the past four weeks to close the last trading session at $10.75, ...
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody ...
ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases, announced progress in its clinical programs and shared insights from its ...
"2024 was a transformational year for ProMIS Neurosciences as we reached a major milestone with the initiation of our 100-patient Phase 1b clinical trial for PMN310, our lead antibody candidate for AD ...
View ProMIS Neurosciences Inc. PMN stock quote prices, financial information, real-time forecasts, and company news from CNN.
Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310 “I have strong conviction in ProMIS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results